CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in June. Details are as follows:
JMP Securities Life Sciences Conference
||Tuesday, June 20, 2017
||Gene Editing - Pushing the Frontier for Curing Disease
||9:00 a.m. ET
Goldman Sachs Third Annual Innovation Symposium
||Tuesday, June 27, 2017
||CRISPR - The Era of Gene Editing
||10:15 a.m. ET
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Editas Media Contact
Pure Communications, Inc.
Editas Investor Contact
Editas Medicine, Inc.